Fate Therapeutics
Fate Therapeutics develops off-the-shelf cell therapies using engineered human induced pluripotent stem cells (iPSCs).
8-KNov 16Latest SEC filing
Nov 12Latest story
November 2026
September 2026
August 2026
Fate Therapeutics develops off-the-shelf cell therapies using engineered human induced pluripotent stem cells (iPSCs).
November 2026
September 2026
August 2026